| 11419851 |
Oral formulations of pyrrolidine derivatives |
Oliver POHL |
2022-08-23 |
| 11312683 |
Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists |
— |
2022-04-26 |
| 10752583 |
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same |
— |
2020-08-25 |
| 10604482 |
Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists |
— |
2020-03-31 |
| 10478420 |
Oral formulations of pyrrolidine derivatives |
Oliver POHL |
2019-11-19 |
| 10047048 |
Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
— |
2018-08-14 |
| 9962367 |
Oral formulations of pyrrolidine derivatives |
Oliver POHL |
2018-05-08 |
| 9718772 |
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same |
— |
2017-08-01 |
| 9670155 |
Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
— |
2017-06-06 |